The Foundation
What Methylation Is and Why It Matters
Methylation is a biochemical process that happens billions of times per second in a healthy body. It involves the transfer of a methyl group (one carbon atom attached to three hydrogen atoms) from one molecule to another. This simple chemical transfer controls a staggering range of functions: which genes are expressed, how neurotransmitters are made and broken down, how estrogen and other hormones are processed and cleared, how the liver detoxifies foreign compounds, and how DNA is repaired and replicated.
S-adenosylmethionine (SAMe) is the primary methyl donor in the body — the molecule that actually carries out most methylation reactions. SAMe is made from methionine, which in turn requires methylfolate (the active form of folate) and methylcobalamin (active B12) to be regenerated from homocysteine. This is the methylation cycle.
Why this matters for everything: Because methylation is not organ-specific. It runs in every cell. When the methylation cycle slows — due to MTHFR variants, nutrient depletion, or both — the effects show up everywhere simultaneously. A person with impaired methylation doesn't usually have one symptom. They have a pattern of symptoms across multiple systems that looks, confusingly, like several unrelated problems.
The Functional Marker
Homocysteine — The Signal Most Labs Miss
Homocysteine is an amino acid produced during normal metabolism. In a healthy methylation cycle, it is rapidly recycled back to methionine using methylfolate and B12. When methylation is impaired, homocysteine accumulates in the blood.
Elevated homocysteine is not just a marker — it is itself harmful. It damages the inner lining of blood vessels (endothelium), reduces nitric oxide (impairing circulation and blood pressure regulation), increases oxidative stress in brain tissue, and is associated with increased risk of cardiovascular disease, stroke, and cognitive decline.
| Homocysteine Level | Interpretation | Clinical Significance |
|---|---|---|
| < 7 μmol/L | Optimal | Methylation cycle functioning well |
| 7–12 μmol/L | Normal (standard range) but worth monitoring | Mild elevation — worth addressing with methylated B vitamins |
| 12–15 μmol/L | Elevated | Meaningful methylation impairment; associated with cardiovascular risk |
| > 15 μmol/L | High — clinical concern | Significant risk; often associated with MTHFR homozygous variants |
Homocysteine testing is available through any standard lab. It is not routinely ordered. Requesting it is the single most efficient way to assess whether methylation is impaired in practice, even without genetic testing.
The ASD Connection
Cerebral Folate Deficiency and Neurodevelopment
Cerebral Folate Deficiency (CFD) is a condition in which the brain has insufficient folate despite normal levels in the blood. It occurs when folate cannot cross the blood-brain barrier efficiently — either because folate receptor alpha (FRα) is blocked by antibodies, or because unmetabolized folic acid occupies the receptor without activating it.
CFD was first described by Ramaekers et al. in 2002 and has since been documented in association with autism spectrum disorder, Rett syndrome, and other neurodevelopmental conditions. The connection to ASD specifically has been studied by Dr. Richard Frye and colleagues in multiple published clinical trials.
Key Published Studies
The Broader Picture
MTHFR, ADHD, OCD, and Reward System Genes
MTHFR doesn't operate in isolation. It interacts with several other genetic variants that, together, shape how the brain produces and responds to dopamine, serotonin, and endorphins. Understanding these interactions explains why the same methylation issue can present differently in different family members — one person develops ADHD characteristics, another OCD, another anxiety, another depression.
| Gene | Function | If Variant Present | MTHFR Interaction |
|---|---|---|---|
| MTHFR | Converts folate to active form for methylation | Low dopamine/serotonin production, elevated homocysteine | — |
| COMT | Breaks down dopamine and other catecholamines | Dopamine builds up (anxiety, OCD) or depletes too fast (ADHD) | MTHFR affects how much dopamine is produced; COMT affects how it's cleared |
| DRD2 | Dopamine receptor density | Fewer receptors = lower motivation, addiction risk, reward deficiency | Low methylation makes less dopamine; fewer receptors means even less signal |
| OPRM1 | Opioid receptor sensitivity (endorphins) | Blunted pleasure response, seeks stronger stimulation | Low methylation underlies both systems; affects overall reward tone |
When a family carries MTHFR alongside variants in COMT, DRD2, or OPRM1, the reward and regulation system of the brain operates at significantly reduced capacity. OCD, anxiety, ADHD-like traits, emotional dysregulation, and difficulty with motivation or pleasure can all emerge from this same genetic substrate — not as separate diseases, but as different expressions of a common biological environment.
Addressing methylation — restoring the raw material the brain needs to produce and regulate neurotransmitters — often improves all of these simultaneously. Because the root is the same root.